Cancer Clinical Trial Sponsors Increasingly Favor Non-U.S. Sites, FDA Finds
Executive Summary
The number of clinical trials used for registration of anticancer agents performed at least partially outside the U.S. has increased by approximately 50% in the last five years, FDA reported at the American Society of Clinical Oncology annual meeting
You may also be interested in...
AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success
AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix
AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success
AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix
Global Consortium Would Facilitate Early Pediatric Oncology Trials – Cmte.
An international research consortium should be established to facilitate the conduct of Phase I-II trials of pediatric oncology drugs in the U.S. and other countries, members of FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee said at its July 15 meeting